Evoke Pharma Inc. (EVOK)

[Lone Wolf]

The Case for EVOK:

On July 20th, share price plummeted following the release of top line results for their Phase III clinical trial of EVK-001. Not taken into consideration is the anomaly that 28 of the 42 sites the trial took place at revealed positive results. The take-away is that the drug was effective, but the process likely was compromised at the other 12 sites.

On Aug. 4th, EVOK repaid the entire outstanding amount from their loan covenant with Square 1 Bank. Fact-check this but, but this should leave them debt-free!

On Aug. 8th, EVOK added $10mil to their coffers via a placement of stock an warrants with institutional investors. Share price of the offering? $3.08. Warrants can convert at $3.03.

On Aug. 23rd...possibly the most important of recent filings, EVOK submitted a confidentiality filing with the SEC in the AH session ensuring that very few took note of it...thus a non-reaction to the filing, though it appears that, as of yesterday, the markets are waking up to the fact that's it's out there...and the implications: a significant material / clinical event.

Lastly, the float remains tiny at 4.2mil shares and short interest is sitting at a lovely 17%.

Watch this space very closely in the next few days. The stock price appears 'on the move'.

$EVOK